You are here
Dr Jonathan Payne
Dr Jonathan Payne is co-group leader of Child Neuropsychology within the Clinical Sciences theme of the Murdoch Children’s Research Institute and a senior clinical neuropsychologist at the Royal Children’s Hospital and. He is an Honorary Senior Fellow with the University of Melbourne’s Department of Paediatrics. Within the Child Neuropsychology group, Dr Payne heads the Genetics and Neurodevelopmental Disorders team which aims to increase understanding of the neurobiological mechanisms underlying complex neurodevelopmental disorders such as ADHD and autism spectrum disorder by studying neurobehavioural outcomes and the brain-behaviour interface in children with monogenetic conditions, primarily neurofibromatosis type 1 (NF1). His program of research includes cognitive and behavioural phenotyping of genetic disorders and identifying markers of risk for cognitive and behavioural deficits in these conditions. He has a strong interest in clinical trials and was a lead investigator on the STARS study; the largest randomised controlled trial of statins as a targeted treatment for cognitive deficits in children with NF1. He was also the senior investigator on a double baseline trial assessing the efficacy of a home-based reading intervention and is currently involved in randomised controlled trials of methylphenidate (with clinical, cognitive and neuroimaging outcomes) and cognitive training.
Dr Payne’s research has been published in leading journals in his fields of research including Nature Neuroscience, Neurology, JAMA Psychiatry, Human Brain Mapping and Neuropsychology.
- Sherman Fellowship in Neurofibromatosis 1 Research
- Children’s Tumor Foundation Young Investigator Award
- Clinician Scientist Fellowship, Murdoch Children’s Research Institute
Project 1: A multimodal study of social functioning and autism spectrum disorder in children with neurofibromatosis type 1
Project 2: Quantification of GABA in children with neurofibromatosis type 1 using magnetic resonance spectroscopy: a cognitive biomarker?
Project 3: Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a randomized controlled trial
Project 4: Multimodal intervention trial for cognitive deficits in neurofibromatosis type 1: efficacy of computerized cognitive training and stimulant medication
Project 5: Reliability and validity of computerized cognitive outcome tools in neurofibromatosis type 1
Payne JM, Porter MA, Pride NA, North KN (2016). Theory of mind in children with neurofibromatosis type 1. Neuropsychology, 16, 439-48.
Walsh KS, Janusz J, Wolters PL, Martin S, Klein-Tasman B, Toledo-Tamula MA, Thompson HL, Payne JM , Hardy KK, de Blank PMK, Semerjian C, Gray LS, Solomon SE, Ullrich N (2016). Neurocognitive outcomes in neurofibromatosis clinical trials. Neurology, 87, S21-S30.
Arnold SS, Barton BA, McArthur G, North KN , Payne JM (2016). Phonics training improves reading in children with neurofibromatosis type 1. Journal of Pediatrics, 177, 219-26.
Morris SM, Acosta MT, Garg S, Green J, Huson S, Legius E, North KN, Payne JM, Plasschaert E, Frazier TW, Weiss LA, Zhang Y, Gutmann DH, Constantino JN (2016). Disease burden and symptom structure of autism in neurofibromatosis type 1: a study of the International NF1-ASD Consortium Team (INFACT). JAMA Psychiatry, 73, 1276-84.
Payne JM, Barton B, Ullrich NJ, Cantor A, Hearps SJC, Cutter G, Rosser T, Walsh KS, Gioia GA, Wolters PL, Tonsgard J, Schorry E, Viskochil D, Klesse L, Fisher M, Gutmann DH, Silva AJ, Hunter SJ, Rey-Casserly C, Cantor NL, Byars AW, Stavinoha PL, Ackerson JD, Armstrong CL, Isenberg J, O’Neil SH, Packer RJ, Korf B, Acosta MT, North KN (2016). A randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology, 87, 1-10.
Lewis AK, Porter MA, Williams TA, Bzishvili S, North KN, Payne JM (2017). Facial emotion recognition, face scan paths, and face perception in children with neurofibromatosis type 1. Neuropsychology, 31, 361-70.
Pride NA, Korgaonkar M, North KN, Payne JM (2017). Impaired engagement of the ventral attention system in neurofibromatosis type 1. Brain Imaging and Behavior. doi: 10.1007/s11682-017-9717-8.
Pride NA, Korgaonkar M, North KN, Barton B, Payne JM (2017). The neural basis of deficient response inhibition in children with neurofibromatosis type 1: evidence from a functional MRI study. Cortex, 93, 1-11. doi.org/10.1016/j.cortex.2017.04.022
Arnold SS, Payne JM , Lorenzo J, North KN, Barton B (in press). Preliteracy impairments in young children with neurofibromatosis type 1. Developmental Medicine & Child Neurology. doi: 10.1111/dmcn.13768
Lewis AK, Porter MA, Williams TA, Bzishvili S, North KN, Payne JM (in press). Reduced attention to faces in children with neurofibromatosis type 1: eye-tracking within a social context. Developmental Medicine & Child Neurology. doi: 10.1111/dmcn.13928.
- United States Army Medical Research and Materiel Command
- Children’s Tumor Foundation, USA
- Children’s Tumour Foundation, Australia
- Murdoch Children’s Research Institute